UltraSight names Rick Geoffrion chairman of the board

By AI, Created 4:30 PM UTC, May 19, 2026, /AGP/ – UltraSight appointed veteran medtech executive Rick Geoffrion as chairman of the board as the company pushes to expand AI-guided cardiac ultrasound in hospitals and health systems. The move comes as demand for cardiac imaging rises and staffing shortages continue to slow echocardiography access.

Why it matters: - UltraSight is trying to scale AI-guided cardiac ultrasound across hospitals, health systems and strategic partners. - The company’s focus is expanding access to cardiac imaging in settings where demand is rising and staffing gaps can delay studies. - The appointment adds a board leader with deep cardiovascular commercialization experience to support that growth.

What happened: - UltraSight appointed Rick Geoffrion as chairman of the board. - The announcement was made May 19, 2026. - UltraSight is based in Boston. - Geoffrion brings more than 35 years of medical technology leadership experience. - More than 30 of those years were in cardiovascular businesses spanning interventional cardiology, circulatory support, structural heart and device commercialization.

The details: - Geoffrion founded, co-founded or led restructurings of six cardiovascular device companies. - Five of those companies were acquired by larger medtech firms. - His exits include Impella, where he served as chairman before the company was acquired by Abiomed and later Johnson & Johnson. - Other exits included Mitralign, acquired by Edwards Lifesciences; Circulite, acquired by HeartWare; FlowMedica, acquired by AngioDynamics; and Pathway Medical, acquired by Bayer. - Geoffrion has raised more than $200 million in venture capital over his career. - He has also held executive roles at Boston Scientific, SciMed Life Systems, PercuSurge, Olympus and Baxter. - Geoffrion currently serves as founder, president and CEO of Cyrano Therapeutics. - He is vice chairman of The Mullings Group. - He serves on the External Advisory Council of the Cleveland Clinic. - He is a member of the executive committee and board of directors of the Medical Device Innovation Consortium, a public-private partnership involving the FDA, CMS and the medical device industry. - UltraSight’s Echosystem combines structured training, real-time AI guidance and advanced analytics. - The platform is designed to help non-cardiac sonographer providers perform focused echocardiography exams under qualified physician oversight. - UltraSight says the system is meant to deliver diagnostic-grade image quality at the point of care while preserving physician-led interpretation and reporting. - The company says the Echosystem can help health systems expand imaging access, reduce wait times and change workflows across inpatient, outpatient, oncology and screening settings. - UltraSight’s software has FDA 510(k) clearance to assist medical professionals in performing cardiac ultrasound scans. - The Echosystem supports focused and limited transthoracic echocardiography workflows that generally align with existing U.S. Medicare reimbursement pathways. - UltraSight’s website and company contacts were listed as www.ultrasight.com and info@ultrasight.com.

Between the lines: - Geoffrion’s track record suggests UltraSight wants a chairman with proven experience turning cardiovascular technologies into commercial exits. - The timing points to a broader push to make AI-guided ultrasound a workflow tool for health systems, not just a clinical technology. - The company is positioning itself around access, oversight and speed, which are the main pressure points in hospital imaging today.

What’s next: - UltraSight said it will continue expanding the UltraSight platform across health systems and deepen strategic partnerships. - Geoffrion said he sees significant opportunity as the company scales. - The company’s near-term challenge is likely to be converting clinical and partner interest into broader hospital adoption.

The bottom line: - UltraSight is adding a veteran cardiovascular operator to help push AI-guided cardiac ultrasound deeper into mainstream hospital workflows.